These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 37330413)

  • 41. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
    Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L
    Eur Urol; 2024 Oct; 86(4):301-311. PubMed ID: 38811314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.
    Zheng J; Qin C; Wang Q; Tian D; Chen Z
    EBioMedicine; 2024 May; 103():105109. PubMed ID: 38614009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biomarkers in muscle invasive bladder cancer.
    Wilson F; Joseph N; Choudhury A
    Adv Clin Chem; 2022; 107():265-297. PubMed ID: 35337604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of circulating tumor DNA in operable non-small cell lung cancer: a systematic review and reconstructed individual patient-data based meta-analysis.
    Chen D; Guo J; Huang H; Tian L; Xie Y; Wu Q
    BMC Med; 2023 Nov; 21(1):467. PubMed ID: 38012727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment.
    Zhou J; Mo H; Hu D; Zhao X; Zhou H; Pan J
    Cancer Med; 2023 Oct; 12(19):19794-19806. PubMed ID: 37746916
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
    Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
    Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.
    Gurung PMS; Barnett AR; Wilson JS; Hudson J; Ward DG; Messing EM; Bryan RT
    Eur Urol Focus; 2020 Jul; 6(4):683-697. PubMed ID: 30803927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis.
    O'Sullivan NJ; Temperley HC; Kyle ET; Sweeney KJ; O'Neill M; Gilham C; O'Sullivan J; O'Kane G; Mehigan B; O'Toole S; Larkin J; Gallagher D; McCormick P; Kelly ME
    Int J Colorectal Dis; 2024 May; 39(1):82. PubMed ID: 38809315
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Kimura S; Iwata T; Abufaraj M; Janisch F; D'Andrea D; Moschini M; Al-Rawashdeh B; Fajkovic H; Seebacher V; Egawa S; Shariat SF
    Clin Genitourin Cancer; 2020 Apr; 18(2):78-87. PubMed ID: 31889669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Wang Y; Song Y; Qin C; Zhang C; Du Y; Xu T
    Ann Med; 2023; 55(2):2281654. PubMed ID: 37963224
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.
    Kim KH; Lee HW; Ha HK; Seo HK
    Investig Clin Urol; 2023 May; 64(3):202-218. PubMed ID: 37341001
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.
    Xiao Y; Ju L; Qian K; Jin W; Wang G; Zhao Y; Jiang W; Liu N; Wu K; Peng M; Cao R; Li S; Shi H; Gong Y; Zheng H; Liu T; Luo Y; Ma H; Chang L; Li G; Cao X; Tian Y; Xu Z; Yang Z; Shan L; Guo Z; Yao D; Zhou X; Chen X; Guo Z; Liu D; Xu S; Ji C; Yu F; Hong X; Luo J; Cao H; Zhang Y; Wang X
    Clin Transl Med; 2022 Aug; 12(8):e1008. PubMed ID: 35968916
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recurrence Prediction by Circulating Tumor DNA in the Patient with Colorectal Liver Metastases After Hepatectomy: A Prospective Biomarker Study.
    Liu W; Jin KM; Zhang MH; Bao Q; Liu M; Xu D; Wang K; Xing BC
    Ann Surg Oncol; 2023 Aug; 30(8):4916-4926. PubMed ID: 37219651
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer.
    Sawasdee A; Tanthanuch M; Bejrananda T
    Asian Pac J Cancer Prev; 2022 Nov; 23(11):3641-3647. PubMed ID: 36444575
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis.
    Guo K; Lu J; Lou Y; Zheng S
    Ther Adv Med Oncol; 2023; 15():17588359231177008. PubMed ID: 37256023
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    Birkenkamp-Demtröder K; Christensen E; Nordentoft I; Knudsen M; Taber A; Høyer S; Lamy P; Agerbæk M; Jensen JB; Dyrskjøt L
    Eur Urol; 2018 Apr; 73(4):535-540. PubMed ID: 28958829
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
    Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
    PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.